Intravitreal Lucentis (Ranibizumab) as A Treatment for Diffuse Diabetic Macular Edema
DOI:
https://doi.org/10.59992/IJSR.2024.v3n6p3الكلمات المفتاحية:
Lucentis (Ranibizumab)، Diabetic، Macular Edema، Vascular Endothelial Growth Factorالملخص
Introduction: Humanized anti-VEGF (Vascular endothelial growth factor) antibody fragment Lucentis (Ranibizumab) is prescribed to treat neovascular (wet) age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It is also used to treat macular edema following retinal vein occlusion.
Objective: This study was carried out to evaluate the anatomic effect and visual acuity response following intravitreal Lucentis (Ranibizumab).
Methodology: In this investigation, diffuse diabetic macular edema was present in 30 eyes belonging to 30 patients with stable diabetes mellitus. Every eye had undergone argon laser photocoagulation, either Focal, Grid, or pan-retinal photocoagulation (PRP), for a minimum of three months. The patients with a mean age was 58.13±5.17 years were treated with two intravitreal injections of 0.5 mg of ranibizumab in 0.05 ml spaced four weeks apart. A skilled ophthalmologist assessed each patient's best-corrected visual acuity (BCVA), also assessed their central macular thickness (CMT) using optical coherence tomography, and assessed their diabetic retinopathy at both the baseline and follow-up sessions.
The results: The results showed that the means of BCVA were significantly (P<0.01) decreased from baseline (1.189±0.077 logMAR) to 1 month (0.162±0.058 logMAR) and 3 months (1.109±0.049 logMAR) after injection. Also the results revealed that the mean of CMT were significantly (P<0.01) declined from the baseline (477.47±151.32 µm) to 1 month (438.27±115.68 µm) and 3 month (396.80±115.26 µm) after treatment.
Conclusions: The study concluded that after three months of the second injection of Lucentis (ranibizumab) significantly reduced central macular thickness and improved visual acuity, then diffuse diabetic macular edema is significantly improved and treated using Lucentis (ranibizumab).
المراجع
Jusufbegovic D, Mugavin MO, Schaal S. Evolution of controlling diabetic retinopathy: Changing Trends in the Management of Diabetic Macular Edema at a Single Institution over the Past Decade. Retina 2015; 35:929–34.
2. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study Report no. 4. The Early Treatment Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin 1987; 27:265–72.
3. Ozkaya A, Alagoz C, Alagoz N, Gunes H, Yilmaz I, Perente I, et al. Dexamethasone implant in pseudophakic and nonglauco- matous subgroup of diabetic macular edema patients: a real life experience. Eur J Ophthalmol 2016; 26:351–5.
4. Diabetic Retinopathy Clinical Research Network, Elman MJ, Ai- ello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, et al. Randomized trial evaluating ranibizumab plus prompt or de- ferred laser or triamcinolone plus prompt laser for diabetic mac- ular edema. Ophthalmology 2010; 117:1064–77.e35.
5. Diabetic Retinopathy Clinical Research Network. A random- ized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Oph- thalmology 2008; 115:1447–9.
6. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al; RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser ver- sus laser monotherapy for diabetic macular edema. Ophthal- mology 2011; 118:615–25.
7. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al; RISE and RIDE Research Group. Ranibizumab for dia- betic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789–801.
8. Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM; TREX-DME Study Group. Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Dia- betic Macular Edema: TREX-DME 1 Year Outcomes. Ophthal- mology 2017; 124:74–81.
9. Menchini U, Bandello F, De Angelis V, Ricci F, Bonavia L, Vio- la F, et al. Ranibizumab for Visual Impairment due to Diabetic Macular Edema: Real-World Evidence in the Italian Population (PRIDE Study). J Ophthalmol 2015; 2015:324841.
10. Ghanchi F, Hazel CA. South Asian diabetic macular oedema treated with ranibizumab (ADMOR)-real-life experience. Eye (Lond) 2016; 30:133–8.
11. Genentech Inc., FDA Approves Genentech Medicine for Diabetic Retinopathy in People with Diabetic Macular Edema. FDA. 2015.
12. US Food and Drug Administration. FDA Approves New Biologic Treatment for Wet Age-Related Macular Degeneration. 2006.
13. US Food and Drug Administration. FDA approves Lucentis to treat diabetic macular edema. 2012.
14. Genentech Inc., FDA Approves Lucentis® (Ranibizumab Injection) for Treatment of Diabetic Macular Edema (DME)--First Major Treatment Advance in More Than 25Years for Sight-Threatening Condition. 2012.
15. Hugin. Ranibizumab significantly more effective than standard of care in treating vision loss due to DME, a serious complication of diabetes. 2010.
16. American Diabetes Association. Diabetes Basics. 2012.
17. Ciulla TA, Amador AG, Zinman B. Diabetic Retinopathy and Diabetic Macular Edema: Pathophysiology, screening, and novel therapies. Diabetes Care. 2003; 26(9):2653‒2664.
18. Macular Edema in Diabetes. Medscape Reference Drugs, Diseases, & Procedures. 2012.
19. American Diabetes Association. Clinical Practice Recommendations and Standards of Medical Care in Diabetes. 2016.
20. Handelsman Y, Mechanick JI, Blonde L, et al. AACE Task Force for Developing a Comprehensive Diabetes Care Plan. EndocrPract. 2011; 17(Suppl. 2):1‒53.
21. American Academy of Ophthalmology. The Eye MD Association. 2008.
22. The Diabetes Control and Complications Trial Research Group. The Ef- fect of Intensive Treatment of Diabetes on the Development and Pro- gression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. N Engl J Med. 1993; 329:977‒986.
23. Nguyen QD, Shah SM, Khwaja AA, et al. READ-2 Study Group. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2010; 117:2146-51.
24. Soheilian M., Ramezani A., Obudi A., et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009; 116:1142-50.
25. Ferrara N., Domico L., Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age- related macular degeneration. Retina. 2006; 26:859-70.
25. Photocoagulation for diabetic macular edema. Early Treat- ment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985; 103:1796-1806.
